Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003411 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003411: Completed Phase 1 study, sponsored by University of Pittsburgh.
NCT00003411 is a Phase 1 study that has completed, run by University of Pittsburgh. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003411, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus motexafin gadolinium in treating patients with bile duct, gallbladder, or pancreatic cancer that cannot be removed surgically.
Interventions
- RADIATION radiation therapy
- DRUG motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00003411 record still lists
NCT00003411 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003411 about?
NCT00003411 is a clinical study titled "Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to treatment. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus motexafin gadolinium in...
What is the current status of trial NCT00003411?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-11. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003411?
The interventions under investigation include: radiation therapy (RADIATION), motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00003411?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia